摘要
This editorial refers to ‘Interleukin-12p40 deficiency attenuates myocardial ferroptosis in doxorubicin-induced chronic cardiomyopathy by inhibiting Th17 differentiation and interleukin-17A production’, by J. Zhang et al., https://doi.org/10.1093/cvr/cvae208. The number of cancer survivors continues to increase due to advances in early detection and treatment. Nevertheless, cancer therapies often contribute to long-term side effects. Cardiovascular complication is a leading cause of morbidity and mortality among cancer survivors, with chemotherapy-induced cardiotoxicity being a major contributing factor.1 Anthracyclines including doxorubicin (DOX) are the best studied anticancer medicines with established cardiotoxicity. Approximately 9% of patients treated with DOX or its derivatives develop heart failure that can happen a long time after cessation of the chemotherapy. Although oxidative stress has been well characterized as the primary cause, pharmacological interventions targeting oxidative stress were not successful for preventing DOX-induced cardiotoxicity (DIC).2 New insights into the cellular and molecular mechanisms underlying the pathogenesis of DIC are needed to assist therapeutic development to prevent or reverse heart failure associated with this most widely prescribed chemotherapeutic drug. Inflammation has been a hallmark of heart failure as evidenced by elevated circulating levels of pro-inflammatory cytokines in patients with heart failure particularly those with reduced ejection fraction compared with healthy individuals.3 T cell-mediated immune imbalance after chemotherapy has been acknowledged early on and is increasingly being recognized as valuable. While T cells contribute to antitumour immunity, their effects in the heart after DOX treatment remain unclear. Recently, CD8+ T cells have been demonstrated as a key driver of DIC.4 DOX treatment results in increased proportion of cardiac CD8+ but not CD4+ T cells in mice. In particular, DOX promotes interferon-γ expression and degranulation of CD8+ T cells in both the circulation and the heart. Depletion of CD8+ and CD4+ T cells using monoclonal antibodies respectively demonstrated reduced and worsened DOX-induced systolic dysfunction and cardiac fibrosis, indicating that CD8+ T cells promote DIC whereas CD4+ T cells regulate CD8+ T cell activity. CD4+ T cells exhibit greater heterogeneity, consisting of pro-inflammatory subsets such as T helper (Th) 1, Th2, Th17, and Th22, alongside an anti-inflammatory regulatory T cell (Treg) subset. Therefore, depletion of CD4+ T cells results in the removal of both pro- and anti-inflammatory subsets. A parallel observation was noted in the adult heart after myocardial infarction (MI), where depletion of CD4+ T cells using monoclonal antibodies similarly exacerbates cardiac fibrosis.5 These data may suggest a protective role of CD4+ T cells against the development of cardiac fibrosis in the adult heart. Importantly, further investigation is needed to determine the specific contribution of individual CD4+ T cell subsets to DIC. In the latest issue of Cardiovascular Research, Zhang et al.6 demonstrated that Th17 cells serve as mediators in DIC, providing a new insight into how a specific CD4+ T cell subset contributes to cardiotoxicity after chemotherapy. The team has found that the expression level of interleukin (IL)-12p40, a shared subunit of IL-12 and IL-23, was significantly increased in mice after DOX treatment. IL-12p40 was predominantly expressed by cardiac CD4+ T cells. Adoptive transfer of CD4+ T cells from IL-12p40 knockout mice failed to promote DOX-induced cardiac fibrosis and cardiomyocyte death in Rag−/− mice. Furthermore, treatment of recombinant rIL-23 reversed the protective effect of IL-12p40 knockout in CD4+ T cells after adoptive transfer, exacerbating cardiac fibrosis and cardiomyocyte death in DOX-treated Rag−/− mice. These results indicate that the protective mechanism against DIC associated with IL-12p40 deficiency is IL-23-dependent. Given the importance of IL-23 in Th17 differentiation and function,7 the team then examined whether the IL23/Th17 axis contributes to DIC. Treatment of rIL-17A abolished the protective effects of IL-12p40 deficiency. Conversely, neutralizing IL-17A alone was sufficient to reduce cardiac fibrosis and cardiomyocyte death after DOX treatment. To date, the iron chelator dexrazoxane stands as the sole FDA-approved drug for the prevention of DIC. The formation of DOX-iron complex within cells has been documented since the 1980s. Studies on genetic iron overload in mice lacking the iron regulatory gene Hfe, both in homozygous and heterozygous knockout models, have indicated increased susceptible to DIC.8 The possible mechanisms underlying iron-mediated DIC include oxidative stress and mitochondrial damage in cardiomyocytes. Recently, ferroptosis, an iron-dependent form of cell death, has emerged as an additional contributor to DIC.9 Nevertheless, how ferroptosis is initiated remains unclear. In the current study, Zhang and colleagues revealed that Th17 cells induce ferroptosis in DOX-treated mice. IL-17A but not IL-23 can directly promote cardiomyocyte ferroptosis by activating the TRAF6/JNK/P53 signalling pathway. Taken together, the current study6 unveils a novel cellular and molecular mechanism that elucidates Th17 cells mediate DIC via IL-17A-induced cardiomyocyte ferroptosis. The findings introduce a clinically relevant therapeutic pathway, IL-12p40/Th17/IL-17A, offering a promising avenue for drug development against DIC from a CD4+ T cell perspective. As aforementioned, the previous work4 has shown that depletion of all CD4+ T cell subsets, including Th17, using anti-CD4 monoclonal antibodies exacerbates DIC. The recent work by Zhang and colleagues prompts speculation about the potential influence of other CD4+ T cell subsets, particularly Treg, in the regulation of DIC. Prior studies have highlighted the role of maintaining a balance between Th17 and Treg in modulating fibrotic responses, a mechanism determining the outcome of heart repair and regeneration during development. Single-cell analysis revealed significantly more CD4+ T cells, mainly Th1 and Th17, in the non-regenerating juvenile than the regenerating neonatal heart after MI.5 Conversely, more Treg are found to accumulate in the injured myocardium after MI. Depletion of Treg in both the neonatal10 and adult5 heart has been demonstrated to cause more severe cardiac fibrosis. The role of Treg in regulating the development of DIC and the molecular mechanisms governing their function in this context remain unknown. An additional question arises regarding why T cell responses after DOX treatment predominantly target the heart over other organ systems. Furthermore, the autoantigen(s) released from the heart after DOX treatment that drive individual T cell responses also require further investigation. In summary, Zhang and colleagues have elegantly highlighted the significance of the Th17 immune response in DIC for the first time (Figure 1). A more comprehensive understanding of the interactions among different T cell subsets is crucial for developing effective therapies to mitigate cardiovascular complications in cancer patients undergoing chemotherapy. The newly discovered role of Th17 cells and the potential role of Treg cells in DOX-induced cardiotoxicity. Th17 cells can induce cardiomyocyte ferroptosis and apoptosis through the secretion of IL-17A when stimulated by IL-23. Presumably, Treg cells may also be activated by IL-23 and could counteract the effects of Th17 cells via secretory factors such as TGF-β, IL-10, and IL-35. The role of Treg cells in the control of DOX-induced cardiac ferroptosis remains to be investigated in future. This image was created with BioRender.com. This work was supported by Research Grants Council of Hong Kong (RFS2223-4S04, 14100021, C7004-22Y, T12-101/23N) and Croucher Foundation to K.O.L. No new data were generated or analysed in support of this research.